DiCE Molecules rallies $80m Series A

DiCE Molecules, a biopharmaceutical company, has closed $80 million in Series C financing.

Iris Dorbian

8 January 2021

DiCE Molecules, a biopharmaceutical company, has closed $80 million in Series C financing. RA Capital Management led the round.

Register now

Get limited access to our industry news, analysis and data, plus regular email updates

Email address

First name

first name

Last name

last name

Organisation

Country Phone number Job title

Job Title

To register, please review and accept our terms and conditions and privacy notice. I accept: sourceRegistration

Not for publication, email or dissemination